

C. Remarks

Independent claim 12 is the sole pending claim, which has been added by the present Amendment. Originally filed claims 1-11 have been cancelled. Support for claim 12 may be found throughout the specification and the originally filed claims, for example at pages 19-21, in Examples 4-7, 9 and 10 and in claim 8. No new matter has been added. Consideration of claim 12 is expressly requested.

Applicants submit herewith sworn translations of priority Japanese Application Nos. 2000-292491 and 2001-284601 in conformity with 37 C.F.R. § 1.55 to perfect the priority claim.

Applicants hereby confirm the provisional election as outlined by the Examiner in paragraph 2 on page 4 of the Office Action.

The specification is objected to because of several informalities. Specifically, the Examiner alleged that the sentence beginning at page 3, line 24, is not clear. Further, the Examiner alleged that formula (1-2) on page 11 is incorrect.

Applicants have amended the specification to correct the informalities identified by the Examiner. Accordingly, this objection should be withdrawn.

Claims 2-5 and 7-11 stand rejected under 35 U.S.C. § 112, second paragraph, as being allegedly indefinite. Because the rejected claims have been cancelled, this rejection is moot and should be withdrawn.

Claims 1-5 and 7-11 stand rejected under 35 U.S.C. § 102(b) as being allegedly anticipated by Maestri et al., "Photochemistry and Luminescence of Cyclometallated Complexes", pp. 1-68 in Advances in Photochemistry, Volume 17 (1992) (Maestri). Claims 1-11 stand rejected under 35 U.S.C. § 102(e) as being allegedly

anticipated by U.S. Patent Application Publication No. 2002/0034656 A1 (Thompson).

Because all rejected claims have been cancelled, these rejections are moot and should be withdrawn.

Applicants respectfully submit that new claim 12 is patentable over Maestri and Thompson. As the Examiner will note, while these references disclose Pt complexes that are, at most, similar to compounds (1) and (2) in claim 12, neither of the complexes contains substituents as presently claimed. In fact, none of such disclosed complexes have substituents other than hydrogen. Accordingly, claim 12 is clearly patentable over Maestri and Thompson, whether these references are considered separately or in combination.

Wherefore, withdrawal of the outstanding rejections and passage to issue of the subject application are respectfully requested.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants

Registration No. 48,512

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200